小结
定义
病史和体格检查
关键诊断因素
- chest pain
- dyspnea
- tachypnea
- presyncope or syncope
- hypotension (systolic BP <90 mmHg)
其他诊断因素
- feeling of apprehension
- cough
- tachycardia
- fever
- unilateral swelling/tenderness of calf
- hemoptysis
- elevated jugular venous pressure
- sternal heave
- accentuated pulmonary component of S2
危险因素
- diagnosis of deep vein thrombosis (DVT)
- major surgery within the preceding 3 months
- medical hospitalization within the preceding 2 months
- active cancer
- previous venous thromboembolic event
- recent trauma or fracture
- increasing age
- pregnancy and postpartum
- varicose veins
- paralysis of the lower extremities
- hereditary thrombophilias
- factor V Leiden mutation
- prothrombin G20210A mutation
- protein C and protein S deficiency
- antithrombin deficiency
- antiphospholipid antibody syndrome
- medical comorbidity
- use of specific drugs
- obesity (BMI ≥29 kg/m²)
- cigarette smoking
- recent long-duration travel
- family history of venous thromboembolic (VTE)
- central venous catheterization
诊断性检查
首要检查
- Pulmonary Embolism Rule-Out Criteria (PERC)
- Wells criteria/Geneva score/YEARS criteria
- D-dimer test
- multiple-detector computed tomographic pulmonary angiography (CTPA)
- ventilation-perfusion (V/Q) scan
- coagulation studies
- BUN and creatinine, hepatic function tests
- CBC
需考虑的检查
- Point-of-care ultrasound (POCUS)
- chest x-ray
- magnetic resonance angiography (MRA)
- pulmonary angiography
- transthoracic echocardiography (TTE)
- electrocardiography (ECG)
- arterial blood gasses (ABG)
- thrombophilia screen
- ultrasonography
- troponin
治疗流程
high risk (massive) PE or high clinical probability of PE with shock or hypotension (i.e., systolic BP <90 mmHg), no contraindication to anticoagulation or thrombolysis
high risk or intermediate-high risk, contraindication to anticoagulation or thrombolysis
intermediate-high risk PESI/sPESI score, no contraindication to anticoagulation or thrombolysis
intermediate-low risk or low risk PESI/sPESI score, no contraindication to anticoagulation
intermediate-low risk or low risk PESI/sPESI score, contraindication to anticoagulation
confirmed PE: provoked
confirmed PE: unprovoked
confirmed PE: pregnant
confirmed PE: cancer-associated
confirmed PE: recurrent PE while on anticoagulation
撰稿人
作者
Scott Stevens, MD
Director
Thrombosis Clinic
Intermountain Medical Center
Murray
Professor of Medicine
Department of Medicine
Intermountain Healthcare and University of Utah
Salt Lake City
UT
利益声明
SS declares that he has no competing interests.
Scott C. Woller, MD
Director
Thrombosis Clinic
Intermountain Medical Center
Murray
Professor
Department of Medicine
Intermountain Healthcare and University of Utah
Salt Lake City
UT
利益声明
SCW declares that he is expecting to receive funding of an investigator initiated grant from Janssen Pharmaceuticals to Intermountain Health with no direct compensation to himself for research in the sum of $500,000 in 2024.
Gabriel V. Fontaine, PharmD, MBA, BCPS
Clinical Pharmacy Manager
Critical Care and Emergency Medicine
Advanced Clinical Pharmacist
Neuroscience Critical Care
Intermountain Medical Center
Murray
UT
利益声明
GVF has received consulting fees and honoraria from AstraZeneca, Chiesi, and Anticoagulation Forum.
鸣谢
Dr Scott M. Stevens, Dr Scott C. Woller, and Dr Gabriel V. Fontaine would like to gratefully acknowledge Drs Geno Merli, Luis H. Eraso, Taki Galanis, Geoffrey Ouma, Miguel Angel de Gregorio, Alicia Laborda, and Seth W. Clemens, previous contributors to this topic.
利益声明
GM has received grants or research support from BMS, J&J, Sanofi-Aventis, Portola, and Janssen; he has served as a Scientific Consultant for BMS, J&J, and Sanofi-Aventis. LHE, TG, GO, MAG, AL, and SWC declare that they have no competing interests.
同行评议者
Keith Wille, MD, MSPH
Associate Professor of Medicine
University of Alabama at Birmingham
Birmingham
AL
利益声明
KW declares that he has no competing interests.
John R. Charpie, MD, PhD
Associate Professor of Pediatrics
Medical Director
Pediatric Cardiothoracic Intensive Care Unit
University of Michigan Congenital Heart Center
C.S. Mott Children's Hospital
Ann Arbor
MI
利益声明
JRC declares that he has no competing interests.
Sanjeev Wasson, MD
Advanced Clinical Fellow
Cleveland Clinic Foundation
Cleveland
OH
Declarações
SW declares that he has no competing interests.
David Jimenez, MD, PhD
Respiratory Physician and Associate Professor
Ramón y Cajal Hospital and Alcalá de Henares University
Respiratory Department and Medicine Department
Madrid
Spain
Declarações
DJ has received consulting fees from Boehringer Ingelheim, Bayer, Leo-Pharm, and Rovi, and lecture fees from Sanofi Aventis.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referências
Principais artigos
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603.Texto completo
Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. 2021 Dec;160(6):e545-608.Texto completo Resumo
American College of Radiology. ACR Appropriateness Criteria®: suspected pulmonary embolism. 2022 [internet publication].Texto completo
Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018 Nov 27;2(22):3317-59.Texto completo Resumo
Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021. Chest. 2024 Aug;166(2):388-404.Texto completo Resumo
Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Angina, unstable
- Myocardial infarction, non-ST elevation (NSTEMI)
- Myocardial infarction, ST-elevation (STEMI)
Mais Diagnósticos diferenciaisDiretrizes
- NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease
- ACR appropriateness criteria: imaging for pulmonary embolism, known clot
Mais DiretrizesFolhetos informativos para os pacientes
Pulmonary embolism: what is it?
Deep vein thrombosis
Mais Folhetos informativos para os pacientesCalculadoras
Pulmonary Embolism Wells Score
Revised Geneva Score for Estimation of the Clinical Probability of Pulmonary Embolism in Adults
Mais CalculadorasVideos
Tracheal intubation: animated demonstration
Bag-valve-mask ventilation: animated demonstration
Mais vídeosConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal